UPDATES FROM ESMO 2024
The RECORD Study + anticoagulants DDI
Professor Amit Bahl
ESMO 2024
PP-NUB-IE-0199-1
Complex mHSPC patient case
Dr. Mark Prentice
ESMO 2024
PP-NUB-IE-0200-1
Just A Minute Video Series
What do the EAU Guidelines tell us about identifying and treating patients with non-metastatic Castration Resistant Prostate Cancer (nmCRPC)?
Professor Philip Cornford
Prostate Cancer Nurse Expert Meeting
What is the Role of the Urology Team in managing patients with non-metastatic Castration Resistant Prostate Cancer (nmCRPC)?
Professor Philip Cornford
Prostate Cancer Nurse Expert Meeting
What is the Role of Bicalutamide in treating patients with non-metastatic Castration Resistant Prostate Cancer (nmCRPC)?
Professor Philip Cornford
Prostate Cancer Nurse Expert Meeting
Updates on the Clinical Management & Treatment of nmCRPC Patients
MDT Highlights from nmCRPC Webinar
Professor Alison Birtle
Professor Nicolas Mottet
Dr Emmet Jordan
Ms. Catherine Dowling
Dr Daniel Cagney
Update on the Clinical Management & Treatment of nmCRPC Patients
nmCRPC – Value of upfront PSMA-PET?
Professor Nicolas Mottet
Update on the Clinical Management & Treatment of nmCRPC Patients
Treatment Advances in nmCRPC & the role for darolutamide (NUBEQA▼)
Professor Alison Birtle
Update on the Clinical Management & Treatment of nmCRPC Patients
For Xofigo▼ prescribing information, please click here
For Nubeqa▼ prescribing information, please click here
For Vitrakvi▼ prescribing information, please click here
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse events. Reports can also be sent directly to Bayer via this link. Both side effects or quality complaints can be reported to Bayer by email to adr-ireland@bayerhealthcare.com
